<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691587</url>
  </required_header>
  <id_info>
    <org_study_id>KB001-04</org_study_id>
    <nct_id>NCT00691587</nct_id>
  </id_info>
  <brief_title>Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanigen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudomonas aeruginosa is an opportunistic pathogen that rarely causes disease in healthy
      people, but is a significant problem for critically ill or immunocompromised individuals.
      Experts estimate that there are greater than 100,000 patients in the United States, Europe
      and Japan where Pseudomonas pneumonia occurs. Patients with Pseudomonas pneumonia currently
      represent only about 20% of the patients in the hospital who get Pseudomonas infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will evaluate KB001 in patients in the intensive care setting who are receiving
      ventilator therapy and who have Pseudomonas infections. They will receive either placebo, or
      one of two dose levels of KB001, a Humaneeredâ„¢, high-affinity antibody fragment that KaloBios
      is developing for the treatment of Pseudomonas aeruginosa (Pa) infections. This trial will
      evaluate the ability of KB001 to protect host epithelium and immune cells, and evaluate
      reduction of pulmonary Pa burden.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of a single dose of KB001.</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the pharmacodynamic effects of a single-dose of KB001.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose KB001, a monoclonal antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose KB001, a monoclonal antibody</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KB001</intervention_name>
    <description>Single low-dose, administered intravenously</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KB001</intervention_name>
    <description>Single high-dose, administered intravenously</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo single-dose, administered intravenously</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent obtained from patient or patient's surrogate if
             unconscious or altered sensorium

          -  Age &gt;18 years

          -  On mechanical ventilation and expected to remain mechanically ventilated for at least
             3 days

          -  Documented pulmonary Pa colonization

        Exclusion Criteria:

          -  Patients with known chronic pulmonary infection with Pa (i.e., patients with cystic
             fibrosis)

          -  Patient currently diagnosed with Pa VAP

          -  Change in systemic antibiotic therapy active against Gram negative bacteria within 72
             hours

          -  Use of an investigational medication within 4 weeks prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jean Chastre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital La Pitie Salpetriere</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Cities</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>July 29, 2009</last_update_submitted>
  <last_update_submitted_qc>July 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Tillman Pearce, MD, Chief Medical Officer</name_title>
    <organization>KaloBios Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>mechanical ventilation</keyword>
  <keyword>mechanically ventilated</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>ventilator associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 31, 2012</submitted>
    <returned>July 5, 2012</returned>
    <submitted>January 29, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 11, 2013</submitted>
    <returned>March 13, 2013</returned>
    <submitted>May 20, 2015</submitted>
    <returned>June 3, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

